Novavax Stock Price To Sales

NVAX Stock

USD 8.62 0.13 1.49%

Novavax fundamentals help investors to digest information that contributes to Novavax's financial success or failures. It also enables traders to predict the movement of Novavax Stock. The fundamental analysis module provides a way to measure Novavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novavax stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	0.49	0.47

Price To Sales Ratio is likely to drop to 0.47 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novavax Company Price To Sales Analysis

Novavax's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Novavax Price To Sales

1.56 X

Most of Novavax's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novavax Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Novavax is extremely important. It helps to project a fair market value of Novavax Stock properly, considering its historical fundamentals such as Price To Sales. Since Novavax's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novavax's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novavax's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Net Receivables	Intangible Assets	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.55	-0.89	-0.91	0.93	0.96	0.99	0.88	-0.46	0.63	-0.37	0.33	-0.98	0.87	0.77	0.96	-0.19	-0.62	0.47	0.94	-0.21	0.67	-0.41	-0.61	-0.78
Total Stockholder Equity	-0.55		0.42	0.79	-0.72	-0.76	-0.48	-0.4	0.35	0.0	0.15	-0.19	0.67	-0.74	-0.3	-0.46	0.71	0.99	-0.27	-0.68	0.13	-0.59	0.92	0.93	0.45
Net Debt	-0.89	0.42		0.69	-0.83	-0.83	-0.91	-0.76	0.23	-0.57	0.46	-0.03	0.87	-0.66	-0.85	-0.76	0.23	0.5	-0.18	-0.72	-0.02	-0.35	0.34	0.58	0.58
Retained Earnings	-0.91	0.79	0.69		-0.93	-0.97	-0.85	-0.77	0.5	-0.41	0.28	-0.33	0.95	-0.97	-0.54	-0.89	0.38	0.83	-0.52	-0.98	0.25	-0.79	0.68	0.78	0.77
Accounts Payable	0.93	-0.72	-0.83	-0.93		0.96	0.89	0.68	-0.41	0.6	-0.36	0.17	-0.96	0.93	0.57	0.87	-0.32	-0.77	0.39	0.91	-0.16	0.63	-0.59	-0.82	-0.71
Total Liab	0.96	-0.76	-0.83	-0.97	0.96		0.93	0.82	-0.47	0.49	-0.34	0.32	-0.98	0.93	0.69	0.9	-0.38	-0.81	0.46	0.96	-0.21	0.72	-0.63	-0.78	-0.76
Total Current Assets	0.99	-0.48	-0.91	-0.85	0.89	0.93		0.87	-0.45	0.67	-0.38	0.36	-0.95	0.8	0.83	0.93	-0.16	-0.57	0.47	0.89	-0.21	0.63	-0.32	-0.54	-0.76
Net Receivables	0.88	-0.4	-0.76	-0.77	0.68	0.82	0.87		-0.38	0.35	-0.43	0.31	-0.85	0.74	0.78	0.87	-0.15	-0.45	0.34	0.85	-0.14	0.6	-0.34	-0.36	-0.72
Intangible Assets	-0.46	0.35	0.23	0.5	-0.41	-0.47	-0.45	-0.38		-0.29	0.08	-0.53	0.44	-0.43	-0.29	-0.52	-0.12	0.36	-0.64	-0.53	0.53	-0.59	0.22	0.28	0.49
Short Term Debt	0.63	0.0	-0.57	-0.41	0.6	0.49	0.67	0.35	-0.29		-0.32	0.37	-0.55	0.41	0.42	0.63	0.17	-0.12	0.34	0.48	-0.14	0.42	0.28	-0.12	-0.56
Common Stock	-0.37	0.15	0.46	0.28	-0.36	-0.34	-0.38	-0.43	0.08	-0.32		0.09	0.43	-0.3	-0.33	-0.34	0.22	0.2	0.25	-0.32	-0.27	-0.14	0.05	0.17	0.63
Long Term Debt	0.33	-0.19	-0.03	-0.33	0.17	0.32	0.36	0.31	-0.53	0.37	0.09		-0.24	0.15	0.37	0.36	-0.08	-0.25	0.67	0.35	-0.47	0.68	0.11	0.03	-0.48
Treasury Stock	-0.98	0.67	0.87	0.95	-0.96	-0.98	-0.95	-0.85	0.44	-0.55	0.43	-0.24		-0.93	-0.7	-0.93	0.31	0.73	-0.39	-0.96	0.15	-0.67	0.54	0.72	0.77
Property Plant Equipment	0.87	-0.74	-0.66	-0.97	0.93	0.93	0.8	0.74	-0.43	0.41	-0.3	0.15	-0.93		0.41	0.89	-0.28	-0.75	0.4	0.96	-0.18	0.68	-0.67	-0.76	-0.69
Current Deferred Revenue	0.77	-0.3	-0.85	-0.54	0.57	0.69	0.83	0.78	-0.29	0.42	-0.33	0.37	-0.7	0.41		0.63	-0.23	-0.4	0.31	0.58	-0.12	0.41	-0.17	-0.33	-0.54
Good Will	0.96	-0.46	-0.76	-0.89	0.87	0.9	0.93	0.87	-0.52	0.63	-0.34	0.36	-0.93	0.89	0.63		-0.08	-0.52	0.51	0.96	-0.21	0.73	-0.33	-0.49	-0.81
Short Term Investments	-0.19	0.71	0.23	0.38	-0.32	-0.38	-0.16	-0.15	-0.12	0.17	0.22	-0.08	0.31	-0.28	-0.23	-0.08		0.73	0.25	-0.25	-0.42	-0.34	0.62	0.6	0.25
Net Tangible Assets	-0.62	0.99	0.5	0.83	-0.77	-0.81	-0.57	-0.45	0.36	-0.12	0.2	-0.25	0.73	-0.75	-0.4	-0.52	0.73		-0.29	-0.72	0.11	-0.65	0.86	0.93	0.53
Long Term Debt Total	0.47	-0.27	-0.18	-0.52	0.39	0.46	0.47	0.34	-0.64	0.34	0.25	0.67	-0.39	0.4	0.31	0.51	0.25	-0.29		0.53	-0.82	0.62	-0.15	-0.23	-0.47
Capital Surpluse	0.94	-0.68	-0.72	-0.98	0.91	0.96	0.89	0.85	-0.53	0.48	-0.32	0.35	-0.96	0.96	0.58	0.96	-0.25	-0.72	0.53		-0.26	0.79	-0.57	-0.67	-0.81
Deferred Long Term Liab	-0.21	0.13	-0.02	0.25	-0.16	-0.21	-0.21	-0.14	0.53	-0.14	-0.27	-0.47	0.15	-0.18	-0.12	-0.21	-0.42	0.11	-0.82	-0.26		-0.33	0.07	0.09	0.17
Short Long Term Debt	0.67	-0.59	-0.35	-0.79	0.63	0.72	0.63	0.6	-0.59	0.42	-0.14	0.68	-0.67	0.68	0.41	0.73	-0.34	-0.65	0.62	0.79	-0.33		-0.36	-0.43	-0.77
Net Invested Capital	-0.41	0.92	0.34	0.68	-0.59	-0.63	-0.32	-0.34	0.22	0.28	0.05	0.11	0.54	-0.67	-0.17	-0.33	0.62	0.86	-0.15	-0.57	0.07	-0.36		0.9	0.26
Net Working Capital	-0.61	0.93	0.58	0.78	-0.82	-0.78	-0.54	-0.36	0.28	-0.12	0.17	0.03	0.72	-0.76	-0.33	-0.49	0.6	0.93	-0.23	-0.67	0.09	-0.43	0.9		0.41
Capital Stock	-0.78	0.45	0.58	0.77	-0.71	-0.76	-0.76	-0.72	0.49	-0.56	0.63	-0.48	0.77	-0.69	-0.54	-0.81	0.25	0.53	-0.47	-0.81	0.17	-0.77	0.26	0.41

Click cells to compare fundamentals

Novavax Price To Sales Historical Pattern

Today, most investors in Novavax Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novavax's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novavax price to sales as a starting point in their analysis.

Novavax Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Novavax

Price To Sales Ratio Over Time

Novavax Price To Sales Ratio

Price To Sales Ratio

0.47

At this time, Novavax's Price To Sales Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Novavax has a Price To Sales of 1.5599 times. This is 92.71% lower than that of the Biotechnology sector and 98.41% lower than that of the Health Care industry. The price to sales for all United States stocks is 86.34% higher than that of the company.

Novavax Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.

Novavax is currently under evaluation in price to sales category among its peers.

Novavax ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novavax's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novavax's managers, analysts, and investors.

Environmental

Governance

Social

Novavax Fundamentals

	Return On Equity	-8.98
	Return On Asset	-0.11
	Profit Margin	(0.32) %
	Operating Margin	(1.54) %
	Current Valuation	704.57 M
	Shares Outstanding	160.18 M
	Shares Owned By Insiders	4.37 %
	Shares Owned By Institutions	60.10 %
	Number Of Shares Shorted	41.51 M
	Price To Earning	(1.36) X
	Price To Book	49.52 X
	Price To Sales	1.56 X
	Revenue	983.71 M
	Gross Profit	(156.04 M)
	EBITDA	(487.39 M)
	Net Income	(545.06 M)
	Cash And Equivalents	1.28 B
	Cash Per Share	16.31 X
	Total Debt	229.08 M
	Debt To Equity	8.24 %
	Current Ratio	1.05 X
	Book Value Per Share	(3.29) X
	Cash Flow From Operations	(713.97 M)
	Short Ratio	5.97 X
	Earnings Per Share	(2.18) X
	Target Price	16.0
	Number Of Employees	1.54 K
	Beta	2.09
	Market Capitalization	1.38 B
	Total Asset	1.8 B
	Retained Earnings	(4.82 B)
	Working Capital	(491.25 M)
	Current Asset	287.26 M
	Current Liabilities	76.49 M
	Net Asset	1.8 B

About Novavax Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC